Introduction: Medical treatment of pediatric inflammatory bowel diseases (IBD) has been greatly changed by the introduction of a number of biologic agents that are able to target various players of the immune response. In particular, monoclonal antibodies against the pro-inflammatory cytokine TNF-alpha (TNF) such as infliximab, adalimumab, and golimumab are now in the clinics both in induction and maintenance therapy, and several efforts are currently ongoing to optimize the use of these drugs in children. Areas covered: This review focuses on therapeutic drug monitoring (TDM) of anti-TNF levels and antidrug antibodies (ADAs), in IBD children. A revision of the analytical assays used for assessing anti-TNF plasma levels is also provided. Expert opinion: Although there is a consensus across studies that higher anti-TNF trough levels are associated with a better clinical outcome, and that early anti-TNF serum measurements could be predictive of long-term response, it is still not clear what the best predictive time of sampling is and what the ideal target drug plasma concentration to achieve. Indeed, there are a number of published studies, particularly in pediatric cohorts, limited by the population size analyzed and more prospective large studies are needed to examine the value of these predictive markers.

Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease

Franca R.;Curci D.;Lucafo M.;Decorti G.
;
Stocco G.
2019-01-01

Abstract

Introduction: Medical treatment of pediatric inflammatory bowel diseases (IBD) has been greatly changed by the introduction of a number of biologic agents that are able to target various players of the immune response. In particular, monoclonal antibodies against the pro-inflammatory cytokine TNF-alpha (TNF) such as infliximab, adalimumab, and golimumab are now in the clinics both in induction and maintenance therapy, and several efforts are currently ongoing to optimize the use of these drugs in children. Areas covered: This review focuses on therapeutic drug monitoring (TDM) of anti-TNF levels and antidrug antibodies (ADAs), in IBD children. A revision of the analytical assays used for assessing anti-TNF plasma levels is also provided. Expert opinion: Although there is a consensus across studies that higher anti-TNF trough levels are associated with a better clinical outcome, and that early anti-TNF serum measurements could be predictive of long-term response, it is still not clear what the best predictive time of sampling is and what the ideal target drug plasma concentration to achieve. Indeed, there are a number of published studies, particularly in pediatric cohorts, limited by the population size analyzed and more prospective large studies are needed to examine the value of these predictive markers.
2019
Pubblicato
https://www.tandfonline.com/doi/abs/10.1080/17425255.2019.1630378?journalCode=iemt20
File in questo prodotto:
File Dimensione Formato  
Expert opinion Therapeutic drug monitoring to improve outcome of anti TNF drugs in pediatric inflammatory bowel disease.pdf

Accesso chiuso

Descrizione: articolo principale
Tipologia: Documento in Versione Editoriale
Licenza: Copyright Editore
Dimensione 767.3 kB
Formato Adobe PDF
767.3 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
2947082_Expert opinion Therapeutic drug monitoring to improve outcome of anti TNF drugs in pediatric inflammatory bowel disease-PostPrint.pdf

accesso aperto

Descrizione: Post Print VQR3
Tipologia: Bozza finale post-referaggio (post-print)
Licenza: Digital Rights Management non definito
Dimensione 919.24 kB
Formato Adobe PDF
919.24 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11368/2947082
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 16
social impact